Clinical Trial Details

Overview

Research Study Summary

Double-blind, Randomized, Placebo-controlled, Parallel-group, Phase IV Study to Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and COPD Exacerbations in Patients with Moderate to Very Severe COPD (ASCENT COPD)

Purpose

This study will be a double-blind, randomized, placebo controlled, parallel-group study to evaluate the effect of Aclidinium bromide on the cardiovascular safety and COPD exacerbations in patients with moderate to very severe COPD, as defined by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria (GOLD, 2011). The Objectives of this study are to assess the safety of Aclidinium bromide on major adverse cardiovascular events (MACE), to assess the overall safety of Aclidinium bromide and to assess whether Aclidinium bromide reduces moderate or severe COPD exacerbations.

To Learn more

CW ID: 203123
Date Last Changed: February 15, 2017

Clinical Trial Snapshot

Phase
4
Gender
Both Male and Female
Age
40 and up
Overall Status
Recruiting
Lead Sponsor
Forest Research Institute
Facility Type
N/A

Contact

Catherine Smith
University of South Florida - Asthma, Allergy & Immunology Clinical Research Unit
13801 Bruce B Downs Blvd, Suite 505
Tampa, FL 33613
Phone: (813)631-4024 x207

View Map

DISCLAIMER: CenterWatch does not conduct clinical research. CenterWatch is a publishing company that posts clinical trials information on behalf of sponsor companies, contract research organizations, clinical research sites and other interested parties. This information is designed to help patients find clinical trials of interest and contact the research centers conducting the trials.